Literature DB >> 9555865

Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230 Arg mutation (LCAT[Fin]) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels.

H E Miettinen1, H Gylling, J Tenhunen, J Virtamo, M Jauhiainen, J K Huttunen, I Kantola, T A Miettinen, K Kontula.   

Abstract

In an attempt to identify genetic factors underlying extreme alterations of serum HDL cholesterol (HDL-C) concentrations, we examined two probands with HDL-C levels <0.2 mmol/L and subsequently screened two large cohorts of smoking men, one with very low (0.2 to 0.7 mmol/L, n=156) and the other with elevated (1.9 to 3.6 mmol/L, n=160) HDL-C levels, for the newly detected mutations as well as some other mutations proposed to affect HDL-C levels. One of the probands had corneal opacities, microalbuminuria, hypertriglyceridemia, and reduced LDL apoprotein B concentration; the other had anemia and presented with stomatocytosis in his peripheral blood. The first proband was found to be homozygous for a novel LCAT Gly230Arg (LCAT[Fin]) mutation, and the second was homozygous for an Arg399Cys mutation we described previously. Transient expression of the mutant LCAT(Fin) cDNA in COS cells disclosed markedly diminished LCAT enzyme activity. In the low-HDL-C group of men (n=156), 8 carriers of LCAT(Fin) and 1 carrier of the LCAT Arg399Cys were identified. In addition, the frequency of the lipoprotein lipase (LPL) Asn291Ser mutation was significantly (P<.05) higher in the low-HDL-C group (4.8%) than in the high-HDL-C group (1.6%). In addition, we identified 1 carrier of the intron 14G-->A mutation of cholesterol ester transfer protein (CETP) in the high-HDL-C group and subsequently demonstrated cosegregation of the mutant allele with elevated HDL-C levels in the proband's family. In conclusion, we have identified a novel LCAT gene Gly230Arg mutation (LCAT[Fin]), which, together with the LPL Asn291Ser mutation, represents a relatively common genetic cause of diminishing HDL-C levels, at least among Finns. This article also reports occurrence of a CETP mutation in subjects having non-Japanese roots.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9555865     DOI: 10.1161/01.atv.18.4.591

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  10 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

2.  A genomewide search using an original pairwise sampling approach for large genealogies identifies a new locus for total and low-density lipoprotein cholesterol in two genetically differentiated isolates of Sardinia.

Authors:  Mario Falchi; Paola Forabosco; Evelina Mocci; Cesare Cappio Borlino; Andrea Picciau; Emanuela Virdis; Ivana Persico; Debora Parracciani; Andrea Angius; Mario Pirastu
Journal:  Am J Hum Genet       Date:  2004-10-11       Impact factor: 11.025

3.  A retractable lid in lecithin:cholesterol acyltransferase provides a structural mechanism for activation by apolipoprotein A-I.

Authors:  Kelly A Manthei; Joomi Ahn; Alisa Glukhova; Wenmin Yuan; Christopher Larkin; Taylor D Manett; Louise Chang; James A Shayman; Milton J Axley; Anna Schwendeman; John J G Tesmer
Journal:  J Biol Chem       Date:  2017-10-13       Impact factor: 5.157

Review 4.  Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review.

Authors:  Eva Boes; Stefan Coassin; Barbara Kollerits; Iris M Heid; Florian Kronenberg
Journal:  Exp Gerontol       Date:  2008-11-17       Impact factor: 4.032

5.  Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse.

Authors:  Anne Braun; Songwen Zhang; Helena E Miettinen; Shamsah Ebrahim; Teresa M Holm; Eliza Vasile; Mark J Post; Danita M Yoerger; Michael H Picard; Joshua L Krieger; Nancy C Andrews; Michael Simons; Monty Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-27       Impact factor: 11.205

Review 6.  Lecithin:cholesterol acyltransferase: old friend or foe in atherosclerosis?

Authors:  Sandra Kunnen; Miranda Van Eck
Journal:  J Lipid Res       Date:  2012-05-07       Impact factor: 5.922

7.  Structure and function of lysosomal phospholipase A2 and lecithin:cholesterol acyltransferase.

Authors:  Alisa Glukhova; Vania Hinkovska-Galcheva; Robert Kelly; Akira Abe; James A Shayman; John J G Tesmer
Journal:  Nat Commun       Date:  2015-03-02       Impact factor: 14.919

8.  Lecithin:cholesterol acyltransferase: symposium on 50 years of biomedical research from its discovery to latest findings.

Authors:  Kaare R Norum; Alan T Remaley; Helena E Miettinen; Erik H Strøm; Bruno E P Balbo; Carlos A T L Sampaio; Ingrid Wiig; Jan Albert Kuivenhoven; Laura Calabresi; John J Tesmer; Mingyue Zhou; Dominic S Ng; Bjørn Skeie; Sotirios K Karathanasis; Kelly A Manthei; Kjetil Retterstøl
Journal:  J Lipid Res       Date:  2020-06-01       Impact factor: 5.922

Review 9.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

10.  LCAT deficiency: a systematic review with the clinical and genetic description of Mexican kindred.

Authors:  Roopa Mehta; Daniel Elías-López; Alexandro J Martagón; Oscar A Pérez-Méndez; Maria Luisa Ordóñez Sánchez; Yayoi Segura; Maria Teresa Tusié; Carlos A Aguilar-Salinas
Journal:  Lipids Health Dis       Date:  2021-07-13       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.